Patents by Inventor Thomas Allen Ceska

Thomas Allen Ceska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IgE ANTIBODIES
    Publication number: 20220235146
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Application
    Filed: December 3, 2021
    Publication date: July 28, 2022
    Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
  • ANTIBODIES SPECIFIC TO FCRN
    Publication number: 20220162311
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: December 9, 2021
    Publication date: May 26, 2022
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Antibodies specific to FCRN
    Patent number: 11220547
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: January 11, 2022
    Assignee: UCB Biopharma SPRL
    Inventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
  • Anti-IgE antibodies
    Patent number: 11214627
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 4, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
  • ANTIBODIES SPECIFIC TO FCRN
    Publication number: 20190270811
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 5, 2019
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • ANTI-IgE ANTIBODIES
    Publication number: 20190144565
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Inventors: Ralph ADAMS, Thomas Allen CESKA, Anna Marie DAVIES, Alistair James HENRY, Xiaofeng LIU, James Michael MCDONNELL, Brian John SUTTON, Marta Katarzyna WESTWOOD
  • Antibodies specific to FcRn
    Patent number: 10273302
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
  • EPITOPES OF IL-17A AND IL-17F AND ANTIBODIES SPECIFIC THERETO
    Publication number: 20180037646
    Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Application
    Filed: September 7, 2017
    Publication date: February 8, 2018
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Thomas Allen Ceska, Alistair James Henry, Jiye Shi
  • Methods of treating an IL-17A mediated pathological condition
    Patent number: 9771420
    Abstract: The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 26, 2017
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
  • ANTIBODIES SPECIFIC TO FCRN
    Publication number: 20160264668
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: November 12, 2014
    Publication date: September 15, 2016
    Inventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
  • Epitopes of IL-17A and IL-17F And Antibodies Specific Thereto
    Publication number: 20150315272
    Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Application
    Filed: June 29, 2015
    Publication date: November 5, 2015
    Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
  • Antibodies specific to IL-17A and IL-17F
    Patent number: 9045537
    Abstract: The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: June 2, 2015
    Assignee: UCB PHARMA SA
    Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
  • Epitopes of IL-17A and IL-17F and Antibodies Specific Thereto
    Publication number: 20140193403
    Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Application
    Filed: February 5, 2014
    Publication date: July 10, 2014
    Applicant: UCB Pharma S.A.
    Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
  • Antibodies specific to IL-17A and IL-17F
    Patent number: 8679494
    Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: March 25, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Thomas Allen Ceska, Alistair James Henry
  • Epitopes Of Il-17a And Il-17f And Antibodies Specific Thereto
    Publication number: 20110262443
    Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Application
    Filed: April 22, 2009
    Publication date: October 27, 2011
    Applicant: UCB PHARMA S.A.
    Inventors: Thomas Allen Ceska, Alistair James Henry, Jiye Shi